Statement of Changes in Beneficial Ownership (4)
September 17 2021 - 4:02PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
COLES N ANTHONY |
2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC.
[
REGN
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
777 OLD SAW MILL RIVER ROAD |
3. Date of Earliest Transaction
(MM/DD/YYYY)
9/15/2021 |
(Street)
TARRYTOWN, NY 10591
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 9/15/2021 | | M(1) | | 6909 | A | $380.95 | 7811 | D | |
Common Stock | 9/15/2021 | | M(1) | | 5039 | A | $345.47 | 12850 | D | |
Common Stock | 9/15/2021 | | S(1) | | 300 | D | $651.36 | 12550 | D | |
Common Stock | 9/15/2021 | | S(1) | | 1101 | D | $652.95 (2) | 11449 | D | |
Common Stock | 9/15/2021 | | S(1) | | 800 | D | $653.31 (3) | 10649 | D | |
Common Stock | 9/15/2021 | | S(1) | | 403 | D | $655.14 (4) | 10246 | D | |
Common Stock | 9/15/2021 | | S(1) | | 1400 | D | $656.48 (5) | 8846 | D | |
Common Stock | 9/15/2021 | | S(1) | | 835 | D | $657.53 | 8011 | D | |
Common Stock | 9/15/2021 | | S(1) | | 935 | D | $658.65 | 7076 | D | |
Common Stock | 9/15/2021 | | S(1) | | 300 | D | $659.0 | 6776 | D | |
Common Stock | 9/15/2021 | | S(1) | | 448 | D | $660.78 (6) | 6328 | D | |
Common Stock | 9/15/2021 | | S(1) | | 3344 | D | $661.56 (7) | 2984 | D | |
Common Stock | 9/15/2021 | | S(1) | | 3 | D | $662.55 | 2981 | D | |
Common Stock | 9/15/2021 | | S(1) | | 905 | D | $663.73 (8) | 2076 | D | |
Common Stock | 9/15/2021 | | S(1) | | 1174 | D | $664.32 (9) | 902 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Non-Qualified Stock Option (right to buy) | $345.47 | 9/15/2021 | | M (1) | | | 5039 | (10) | 1/27/2027 | Common Stock | 5039 | $0.0 | 0 | D | |
Non-Qualified Stock Option (right to buy) | $380.95 | 9/15/2021 | | M (1) | | | 6909 | (10) | 1/2/2028 | Common Stock | 6909 | $0.0 | 0 | D | |
Explanation of Responses: |
(1) | Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). |
(2) | Represents volume-weighted average price of sales of 1,101 shares of Company stock on September 15, 2021 at prices ranging from $652.48 to $652.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 15, 2021 at each separate price. |
(3) | Represents volume-weighted average price of sales of 800 shares of Company stock on September 15, 2021 at prices ranging from $653.11 to $653.52. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 15, 2021 at each separate price. |
(4) | Represents volume-weighted average price of sales of 403 shares of Company stock on September 15, 2021 at prices ranging from $655.14 to $655.49. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 15, 2021 at each separate price. |
(5) | Represents volume-weighted average price of sales of 1,400 shares of Company stock on September 15, 2021 at prices ranging from $656.18 to $656.81. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 15, 2021 at each separate price. |
(6) | Represents volume-weighted average price of sales of 448 shares of Company stock on September 15, 2021 at prices ranging from $660.29 to $660.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 15, 2021 at each separate price. |
(7) | Represents volume-weighted average price of sales of 3,344 shares of Company stock on September 15, 2021 at prices ranging from $661.02 to $661.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 15, 2021 at each separate price. |
(8) | Represents volume-weighted average price of sales of 905 shares of Company stock on September 15, 2021 at prices ranging from $663.15 to $663.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 15, 2021 at each separate price. |
(9) | Represents volume-weighted average price of sales of 1,174 shares of Company stock on September 15, 2021 at prices ranging from $664.00 to $664.63. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 15, 2021 at each separate price. |
(10) | The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
COLES N ANTHONY 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591 | X |
|
|
|
Signatures
|
By: Beverly Dubs as attorney-in-fact For: N. Anthony Coles | | 9/17/2021 |
**Signature of Reporting Person | Date |
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2023 to Jul 2024